IL22 and leukemia: Some data have revealed the elevated Th17 levels in newly-diagnosed AML patients whereas others have shown normal levels in newly-diagnosed AML patients.14,15 Th22, as the newest identified subset of Th cells is clearly separated from Th17 and Th1 subsets with a different identity with respect to function and gene expression.        16  Novel findings have shown that Th22 and its effector cytokine IL-22 are also implicated in the pathogenesis of inflammatory and autoimmune diseases, myelodysplastic syndrome (MDS) and leukemias as AML and ALL.